[go: up one dir, main page]

HK1094167A1 - Monoclonal antibodies to hepatocyte growth factor - Google Patents

Monoclonal antibodies to hepatocyte growth factor

Info

Publication number
HK1094167A1
HK1094167A1 HK07101333.7A HK07101333A HK1094167A1 HK 1094167 A1 HK1094167 A1 HK 1094167A1 HK 07101333 A HK07101333 A HK 07101333A HK 1094167 A1 HK1094167 A1 HK 1094167A1
Authority
HK
Hong Kong
Prior art keywords
growth factor
hepatocyte growth
monoclonal antibodies
pharmaceutical composition
administering
Prior art date
Application number
HK07101333.7A
Other languages
English (en)
Inventor
Kyung Jin Kim
Yi-Chi Su
Original Assignee
Galaxy Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1094167(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galaxy Biotech Llc filed Critical Galaxy Biotech Llc
Publication of HK1094167A1 publication Critical patent/HK1094167A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK07101333.7A 2004-04-15 2007-02-05 Monoclonal antibodies to hepatocyte growth factor HK1094167A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/825,060 US20040208876A1 (en) 2003-04-18 2004-04-15 Monoclonal antibodies to hepatocyte growth factor
PCT/US2004/026565 WO2005107800A1 (en) 2004-04-15 2004-08-13 Monoclonal antibodies to hepatocyte growth factor

Publications (1)

Publication Number Publication Date
HK1094167A1 true HK1094167A1 (en) 2007-03-23

Family

ID=35320045

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07101333.7A HK1094167A1 (en) 2004-04-15 2007-02-05 Monoclonal antibodies to hepatocyte growth factor

Country Status (26)

Country Link
US (5) US20040208876A1 (no)
EP (2) EP2204191A1 (no)
JP (2) JP4594381B2 (no)
KR (1) KR101072736B1 (no)
CN (1) CN1964738A (no)
AT (1) ATE473760T1 (no)
AU (1) AU2004319276C1 (no)
BR (1) BRPI0418745A (no)
CA (1) CA2563080C (no)
CR (1) CR8698A (no)
CY (1) CY1110783T1 (no)
DE (1) DE602004028168D1 (no)
DK (1) DK1734995T3 (no)
ES (1) ES2346886T3 (no)
HK (1) HK1094167A1 (no)
HR (1) HRP20100521T1 (no)
IL (1) IL178474A (no)
MX (1) MXPA06011822A (no)
NO (1) NO20065227L (no)
NZ (1) NZ550324A (no)
PL (1) PL1734995T3 (no)
PT (1) PT1734995E (no)
RU (1) RU2361879C2 (no)
SI (1) SI1734995T1 (no)
WO (1) WO2005107800A1 (no)
ZA (1) ZA200609407B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
ES2523837T3 (es) * 2003-07-18 2014-12-01 Amgen Inc. Agentes de unión específica al factor de crecimiento de hepatocitos
ATE465181T1 (de) * 2004-08-05 2010-05-15 Genentech Inc Humanisierte anti-cmet-antagonisten
MX2007015056A (es) * 2005-06-02 2008-03-11 Galaxy Biotech Llc Metodos para el tratamiento de tumores de cerebro con anticuerpos.
BRPI0617378B8 (pt) 2005-10-14 2022-09-20 Chugai Pharmaceutical Co Ltd Uso de um inibidor de il-6 para produzir uma composição farmacêutica para suprimir dano a um ilhota transplantada depois do transplante de ilhota; e aperfeiçoar a viabilidade de uma ilhota em um transplante de ilhota
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP1967209B1 (en) * 2005-11-25 2012-06-06 Keio University Therapeutic agent for prostate cancer
CN101370521A (zh) 2006-01-27 2009-02-18 学校法人庆应义塾 伴有脉络膜血管生成的疾病的治疗药
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
NZ573819A (en) * 2006-06-02 2011-09-30 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
BRPI0712222B1 (pt) 2006-06-02 2021-10-13 Aveo Pharmaceuticals, Inc. Proteína de ligação isolada que se liga ao fator de crescimento de hepatócito humano (hgf), seu uso e método de produção, ácido nucléico, vetor de expressão, célula hospedeira, e métodos para produzir um polipeptídeo que compreende uma região variável da cadeia pesada de imunoglobulina e para produzir um polipeptídeo que compreende uma região variável da cadeia leve de imunoglobulina
AU2008208321B2 (en) 2007-01-23 2013-03-21 Chugai Seiyaku Kabushiki Kaisha Chronic rejection inhibitor
CA2692165A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
TW201002346A (en) * 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
WO2009140549A1 (en) * 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20120052064A1 (en) * 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
CN101555912B (zh) * 2009-04-29 2012-10-03 深圳市特辰科技股份有限公司 一种转轮式自锁安全制动装置及其工作方法
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
WO2012044577A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
BR112013030472A2 (pt) 2011-06-30 2019-09-24 Genentech Inc formulação farmacêutica, artigo de fabricação e método
CZ303636B6 (cs) * 2011-08-19 2013-01-23 Invos, Spol. S R. O. Biokontejner pro sber bioodpadu a komunálního odpadu
KR20140067052A (ko) 2011-09-09 2014-06-03 암젠 인코퍼레이티드 식도암 및 위암 환자들에서 항-간세포 성장 인자（“ｈｇｆ”） 항체들의 유효성을 예측하기 위한 ｃ―ｍｅｔ 단백질의 용도
WO2013043452A1 (en) 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
KR20150140685A (ko) * 2013-03-14 2015-12-16 앨더 바이오파마슈티컬즈, 인코포레이티드 Hgf에 대한 항체 및 이를 포함하는 조성물
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US722041A (en) * 1902-11-24 1903-03-03 Mail Belting Company Conveyer-belt.
JP2564486B2 (ja) 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
GB9003621D0 (en) 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
EP0922102B1 (en) 1996-07-03 2010-04-21 Genentech, Inc. Hepatocyte growth factor receptor agonists and uses thereof
WO2000012560A1 (en) 1998-08-28 2000-03-09 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
JP2004536605A (ja) 2001-07-26 2004-12-09 イーライ・リリー・アンド・カンパニー インターロイキン１β抗体
EP1516185A4 (en) 2001-12-27 2007-06-20 Van Andel Res Inst Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
WO2004019991A2 (en) 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
KR20110117728A (ko) 2003-06-06 2011-10-27 제넨테크, 인크. Ｈｇｆ 베타 쇄와 ｃ-ｍｅｔ 사이의 상호작용의 변조
DE602004024536D1 (de) 2003-07-07 2010-01-21 Van Andel Res Inst Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors
ES2523837T3 (es) * 2003-07-18 2014-12-01 Amgen Inc. Agentes de unión específica al factor de crecimiento de hepatocitos
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
MX2007015056A (es) 2005-06-02 2008-03-11 Galaxy Biotech Llc Metodos para el tratamiento de tumores de cerebro con anticuerpos.
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
JP4594381B2 (ja) 2010-12-08
KR20070012711A (ko) 2007-01-26
CY1110783T1 (el) 2015-06-10
EP1734995B1 (en) 2010-07-14
AU2004319276A1 (en) 2005-11-17
US20090104192A1 (en) 2009-04-23
IL178474A (en) 2011-04-28
AU2004319276B2 (en) 2010-08-26
AU2004319276C1 (en) 2011-03-03
US7494650B2 (en) 2009-02-24
US7687063B2 (en) 2010-03-30
HRP20100521T1 (hr) 2010-10-31
US20120064066A1 (en) 2012-03-15
BRPI0418745A (pt) 2007-12-11
ATE473760T1 (de) 2010-07-15
SI1734995T1 (sl) 2010-09-30
NZ550324A (en) 2009-12-24
CA2563080A1 (en) 2005-11-17
ZA200609407B (en) 2008-07-30
EP1734995A1 (en) 2006-12-27
NO20065227L (no) 2007-01-10
CA2563080C (en) 2015-01-27
MXPA06011822A (es) 2007-03-23
DE602004028168D1 (de) 2010-08-26
IL178474A0 (en) 2007-02-11
US20070160613A1 (en) 2007-07-12
US20040208876A1 (en) 2004-10-21
US20080019966A1 (en) 2008-01-24
RU2006140257A (ru) 2008-05-20
CN1964738A (zh) 2007-05-16
EP1734995A4 (en) 2007-04-25
RU2361879C2 (ru) 2009-07-20
JP2011012067A (ja) 2011-01-20
ES2346886T3 (es) 2010-10-21
EP2204191A1 (en) 2010-07-07
WO2005107800A1 (en) 2005-11-17
PT1734995E (pt) 2010-08-18
CR8698A (es) 2007-12-17
PL1734995T3 (pl) 2010-12-31
DK1734995T3 (da) 2010-10-25
KR101072736B1 (ko) 2011-10-11
JP2007532643A (ja) 2007-11-15

Similar Documents

Publication Publication Date Title
HK1094167A1 (en) Monoclonal antibodies to hepatocyte growth factor
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
EA201000245A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
DK1684869T3 (da) Fremgangsmåde til terapi af B-celle-relaterede cancersygdomme
IL177069A0 (en) ANTI-EpCAM IMMUNOGLOBULINS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
UA109633C2 (uk) Антитіло людини проти тканинного фактора
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
HK1243943A1 (zh) 使用抗IL-1α抗體治療癌症
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
TW200740845A (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
TR200902344T1 (tr) Anti-epidermal büyüme faktörü reseptör antikorları ile terapinin etkisinin geliştirilmesi için terapötik bileşimler.
SG156658A1 (en) Treatment of diseases